Biomind Labs (BMND.NE) Stock Price

Biomind Labs Price

CLOSED
0.25
​
Market closed

Revenue at Biomind Labs has contracted by 20.3% per year over the past 13 years to 20,000.00 USD. Earnings per share have grown at 166.6% per year over the last 6 years. Biomind Labs's net margin stands at -1,800.0%, down from 532.1% several years earlier.

Biomind Labs stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomind Labs business model & stock analysis

Biomind Labs Inc is a biotechnology company based in Toronto, Canada, operating within the Health Care sector and specifically in the Pharmaceuticals industry. The company has a small team of five full-time employees. Biomind Labs Inc completed its initial public offering (IPO) on July 27, 2021, and trades under the ticker symbol BMND.NE with ISIN CA0907021012. The company's website is https://biomindlabs.com/. Biomind Labs Inc is engaged in the research and development of pharmaceutical drugs and nanotechnology-based delivery systems, with a focus on psychiatric and neurological conditions. The company's platform integrates biology, chemistry, medicine, neuroscience, technology, intellectual property, and pharmaceutical-grade production. It is developing novel formulations of psychedelic molecules, including N,N-dimethyltryptamine (DMT), 5-MeO-DMT, and mescaline, for therapeutic applications. Specific drug candidates under development include BMND05, a novel formulation of 5-MeO-DMT intended for chronic pain treatment, and BMND08, a novel formulation of 5-MeO-DMT targeting Alzheimer's disease. The company's activities are centered around scientific research, clinical trials, and leveraging jurisdictions that offer expedited pathways for drug development and market entry.

Frequently asked questions about Biomind Labs

Converted at the current exchange rate, the Biomind Labs share trades at 0.22 EUR (0.25 USD).

The revenue cannot currently be calculated for Biomind Labs.

The profit cannot currently be calculated for Biomind Labs.

The P/E ratio cannot be calculated for Biomind Labs at the moment.

The P/S cannot be calculated for Biomind Labs currently.

The Eulerpool Quality Score for Biomind Labs is 2/10.

The ISIN of Biomind Labs is CA0907021012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Biomind Labs is A3CSQR. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Biomind Labs is BMND.NE. The ticker symbol is used to trade Biomind Labs shares on the stock exchange.

Fair ValueTerminal
0.20 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
USD
Initial public offering
Jul 27, 2021
ISIN
CA0907021012
Cusip
090702101
Market capitalization
19.35 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
12.57
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
49.00 %
Last updated Oct 18, 2026, 11:58 AM

Biomind Labs Peer Group

Biomind Labs FIGI

BMNDF:US · BBG008LZHJT0BMNDF:PQ · BBG008LZHK71BMNDF:UV · BBG008LZHK80BMND:CN · BBG011YN3745BMND:TR · BBG011YN37F3BMND:TX · BBG011YN37H1BMND:TG · BBG011YN37L6BMND:DT · BBG011YN37T8BMND:DG · BBG011YN37V5BMND:QF · BBG011YN37W4BMND:QH · BBG011YN37X3BMND:DJ · BBG011YN37Y2

All fundamentals and in-depth analysis of Biomind Labs

Our stock analysis for Biomind Labs stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biomind Labs. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.